ments were assessed in 43 regions in the LDL apheresis group and 35 regions in the medication group. In the LDL apheresis group, TJEERD v a n d e r WERF, MD, PhD, FACC Nijmegen, The Netherlands Objectives. In a randomized study we evaluated the effect of biweekly low density lipoprotein (LDL) apheresis plus simvastatin versus medication alone on regional myocardial perfusion.
apheresis is considered a valuable therapeutic option for patients with homozygous FH and for patients with coronary artery disease and hypercholesterolemia refractory to diet and drugs (2) (3) (4) . It has been shown in a number of nonrandomized studies (2,5-8) that plasma exchange or LDL apheresis led to regression or slowing of progression of coronary atheroscle rotic lesions and resolution of xanthomas. The use of plasma exchange was also associated with increased survival among patients with homozygous FH compared with their untreated homozygous siblings (9) . In one recently published randomized trial in patients with FH (10), biweekly LDL apheresis versus drug therapy for 2 years showed no difference in coronary anatomy as measured by quantitative coronary angiography (QCA) (10) . In the LDL-Apheresis Atherosclerosis Regres sion Study (LAARS) (11) , there was also no difference in quantitatively assessed coronary anatomy, but patients under going LDL apheresis had a significant improvement in exercise variables versus patients on drug therapy alone. Questions Abbreviations and Acronyms DSA = digital subtraction angiography FH = familial hypercholesterolemia HMTT = hyperemic mean transit time (of contrast medium) ' LAARS = LDL-Apheresis Atherosclerosis Regression Study LAD = left anterior descending coronaiy artery LCx = left circumflex coronary artery LDL = low density lipoprotein QCA = quantitative coronaiy angiography RCA = right coronary artery 1 ROI = region of interest remain about 1) the cause of this functional improvement, 2) the methods for evaluating the potential benefits in aggressive lipid-lowering therapy, and 3) the impact on patient care. Traditionally, clinical end points, such as improved survival and reduction of major cardiac events, are the best proof of effect in lipid-lowering trials but require numerous patients over a long period of time (12, 13) . Quantitative coronary angiography is the present reference standard for evaluating lipid-lowering therapy in coronary artery disease (14) (15) (16) . However, application of QCA has several limitations, such as the diffuse character of coronaiy artery disease, complexity of stenosis geometry, foreshortening in nonorthogonal views, insufficient contrast staining and limited resolution of the radiographic chain (16) (17) (18) . Moreover, there seems to be a dissociation between the results of angiographic studies and clinical outcome. Lipid-lowering therapy reduces the incidence of cardiovascular events to a greater extent than the propor tionate changes in plaque dimensions suggest (15, 19) . Reduc tion of hypercholesterolemia retards the progression of coro nary atherosclerosis by depleting the lipid core of the plaque and deminishing the inflammatory process; not the change in angiographic lumen size but the process of plaque stabilization appears to decrease the risk of disruption with fewer clinical events (20) . The endothelium plays a major role in regulating the vascular smooth muscle tone. Endothelial dysfunction can result in an impaired blood flow of the large and small coronary arteries (21) (22) (23) (24) (25) . Dysfunction of endotheliummediated vasomotion is associated with atherosclerosis, hyper cholesterolemia and smoking in adults and is already present in the systemic arteries of children with heterozygous FH (21) (22) (23) (24) (25) (26) . Lipid-lowering therapy improves the endotheliummediated vasomotion after relatively short periods of time (27) (28) (29) . The functional improvement of the coronary circula tion precedes structural improvement (30) . The cumulative effects of all anatomic and functional abnormalities of the epicardial coronary arteries in combination with possible dys function of conduit and resistance vessels are responsible for the ultimate effect of atherosclerosis on myocardial perfusion.
In this setting, it should be emphasized that minor changes in lumen diameter of the coronaiy arteries have a major effect on vascular resistance, according to Poisseuille's law.
To evaluate the functional state of the coronaiy circulation after aggressive lipid-lowering therapy with LDL apheresis, we assessed regional myocardial perfusion by means of digital subtraction angiography (DSA) followed by videodensitometric calculation of the hyperemic mean transit time (HMTT) of contrast medium in the LAARS trial.
Methods
The purpose of the study was to compare the effects of aggressive lipid-lowering treatment by LDL apheresis versus conventional treatment on the anatomy and functional state of the coronary tree. The trial design, patient characteristics, methodology of lipid measurements, QCA and exercise testing have been described previously (11) . Briefly, consenting pa tients with extensive coronary artery disease and hypercholes terolemia were randomized to diet and 40 mg of simvastatin once daily with or without biweekly LDL apheresis. The inclusion criteria were 1) male patients between 18 and 70 years old; 2) extensive coronary atherosclerosis demonstrated by cardiac catheterization; 3) total serum cholesterol ^8.0 mmol/liter or LDL cholesterol >5.8 mmol/liter and serum triglycerides ^5.0 mmol/liter during a standard lipid-lowering diet. The ethics committee of the University Hospital of Nijmegen approved the study, The study cohort included 42 male patients with a mean (±SD) age of 52.0 ± 9.2 years (range 29 to 69). The elevated lipid levels were due to heterozygous FH in 32 patients (76%), 16 in each group, In the remaining 10 patients, the diagnosis was primary hypercholes terolemia in 8 (19%) and familial combined hypercholesterol emia in 2 (5%). In the LDL apheresis group, 17 patients had three-vessel disease, and 4 had two-vessel disease, whereas in the medication group 19 patients had three-vessel disease, and 2 had two-vessel disease (a vessel was considered diseased when there was >50% diameter stenosis in a major branch). Before entry into the study, all patients had a 2-month run-in period. Antianginal medication was continued, but lipidlowering medication was stopped. If total cholesterol remained elevated above the lower limit for inclusion into the study, cardiac catheterization and exercise testing were carried out. After cardiac catheterization, patients were randomized in a stratified way, which took into account the total cholesterol and lipoprotein(a) levels, age and history of coronaiy bypass surgery. Antianginal medication was continued at the same doses during the trial. If adaptation in medication was neces sary during the study, the original prescription, if possible, was restored before the follow-up cardiac catheterization. The follow-up cardiac catheterization was performed 1 month after the last LDL apheresis. Low density lipoprotein apheresis was performed with an automated system MA-01 (Kanegafuchi Chemical Industry Co. Ltd, Osaka, Japan) with two small-sized dextran sulfate cellulose columns that were used and regener ated alternately in one procedure, permitting continuous apheresis (11) . Before the start of the LDL apheresis, all patients received 10,000 U of heparin. A volume of 5,000 ml (~1.5 plasma volume) was treated per session. Assessment of regional myocardial perfusion, We used the method of DSA, followed by videodensitometry and calcula tion of the HMTT of contrast to compare the maximal regional myocardial perfusion in the areas of the left anterior descend ing coronaiy artery (LAD), left circumflex coronaiy arteiy (LCx) and right coronary arteiy (RCA) at baseline and at follow-up. This method has been developed in our laboratory and has been validated in model studies, animal experiments and in humans (31) (32) (33) (34) , Before cardiac catheterization, pa tients were trained to hold their breath with use of a nose clamp at maximal inspiration for 15 to 20 s. After completion of angiography of the LAD, the left Judkins catheter with a 7F tip (Cordis) was left in place for the DSA protocol, in which a 60° left anterior oblique projection was used. After angiogra phy of the RCA, the protocol was repeated in the 30° right anterior oblique projection. Meticulous care was taken to repeat the follow-up DSA under exactly the same circum stances, with the same medication.
At the start of the procedure, a 5F stimulation catheter was positioned in the right atrium. During DSA, the heart was triggered in synchrony with the radiographic pulses, slightly above its inherent rate, to provide a strictly regular heart rhythm. Iohexol-350 (Nycomed AS, Oslo, Norway), a nonionic low osmolar contrast agent was used. For all studies, 6 ml of contrast medium was injected, using a power injector at a speed of 4 ml/s. Twenty-five seconds after administration of 8 to 12 mg of papaverine (depending on the size of the vascular bed), the patient was instructed to hold his breath, and image acquisition was started 5 s later followed by contrast injection. One image/heart cycle was obtained just before the onset of the QRS complex. Image acquisition was performed on a Bicor radiograph system connected to a Digitron-3 computer for digital subtraction angiography (Siemens AG, Erlangen, Ger many). Images were generated with the automatic brightness control switched off after the fourth image in every study to enable density calculation. Subsequently, the images were digitized in a 512 X 512 matrix with 1,024 density levels. The image quality was checked immediately after image acquisi tion) and if necessary the imaging protocol was repeated a maximum of three times.
Image and data processing were performed off-line using a Sun SPARC station 10 (Sun Microsystems, Inc.) with pro grammed Khoros software. Circular regions of interest (ROIs) of 200 to 600 pixels were constructed over the tip of the coronary catheter to record the contrast injection and over the myocardium supplied by the respective vessels ( Fig. 1 ). The ROIs were chosen at the myocardial level on predefined localizations, carefully avoiding overlap with major side branches and veins. Close to the myocardial ROI, a back ground ROI was chosen to analyze changes in background density (Fig. 1 ). Time-density curves were generated by sam pling the averaged pixel density within a ROI in consecutive images and, subsequently, these curves were fitted with a gamma-variate function. In case of deviating background den sity, the fitted curves of the myocardial ROIs were corrected with the corresponding background ROI. The HMTT is the difference in the mean transit time of the contrast medium at the myocardial ROI and at the injection site ROI (ROI at catheter tip). Because of the pressure dependency of flow during maximal hyperemia, HMTTs were corrected for a normalized mean aortic blood pressure of 100 mm Hg for comparison between the two studies. This correction was performed by multiplying the mean transit time in seconds by the ratio Pa/100, where Pa is the actual mean blood pressure during image acquisition. If a pressure curve showed a pressure drop or wedging during hyperemia, indicating that the catheter influenced maximal flow, the study was excluded from further analysis. Myocardial areas that were subjected to a Q wave myocardial infarction or occlusion of the proximal vessel were excluded from analysis.
For final analysis, paired time-density curves of sufficient quality without artifacts were selected by a cardiologist (W.R.M.A.) who had no knowledge of treatment allocation. Figure 2 shows an example of paired time-density curves of an ROI. The final data base was composed, and subsequent HMTTs were calculated and corrected for blood pressure, as stated before. Regional myocardial perfusion was assessed by averaging the comparative HMTTs (one to two ROIs) in the area supplied by the LAD, LCx and RCA to one value/ perfusion area per session. Perfusion areas supplied by bypass JACC VoL 28, No. 7 December 1996 :1696 AENGEVAEREN ET AL.
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LDL APHERESIS IMPROVES REGIONAL MYOCARDIAL PERFUSION grafts were also imaged by the DSA protocol, carefully avoid ing evaluation of perfusion areas with competitive flow through native coronary artery and bypass graft. The ROIs of perfusion areas supplied by bypass grafts were classified as part of the original coronary artery region. Analysis of the effect of both lipid-lowering treatments on myocardial perfusion was calculated from HMTT values derived from individual ROIs from a regional" and patient-based assessment of HMTT. The patient-based evaluation was performed by averaging the regional HMTT values to one value per patient as a global estimate of myocardial perfusion. Analysis of the patient-based HM TT values was performed both with and without correction for change in hematocrit. For this correction the HMTT values at follow-up were subtracted by the percent change in hemat ocrit, assuming a linear relation between hematocrit and blood viscosity in this narrow range of actual hematocrit values (35) . Statistical analysis. Comparisons of prespecified continu ous variables within groups were made by two-sided paired t tests and between-group analysis by unpaired t tests for normally distributed data. For categoric comparison, a chisquare test was performed when appropriate. Correlations were tested with the Pearson correlation coefficient. For all hypothesis tests, a two-sided p value <0.05 was considered significant. Results are expressed as mean value ± SD, unless otherwise indicated.
Results
Forty-two male patients were randomized into two groups of 21 patients in our center. The results in both groups for lipid metabolism, QCA, exercise testing and clinical events have been described elsewhere (11) . In short, LDL cholesterol decreased in the LDL apheresis group from 7.78 ± '1.86 mmol/liter to a time-averaged value of 2.95 ±1.13 mmol/liter and from 7.85 ± 2.34 to 4.13 ± 1.58 mmol/liter in the medication group. Quantitative coronary angiography showed no changes in mean segment diameter and minimal obstruc tion diameter within and between the two groups. At exercise tests, in the LDL apheresis group versus the medication group, time to onset of 1-mm (0.1 mV) ST segment depression was prolonged by 39%, and maximal ST segment depression was halved, Clinical characteristics and patient-based study data are shown in Table 1 .
Hyperemic mean transit time. The DSA protocol for cal culation of HMTT was performed in all 42 patients. In the LDL apheresis group, 19 patients completed the 2 years of LDL apheresis; 2 stopped because of progression of angina pectoris after 3 and 10 months, respectively. Both patients underwent coronaiy artery bypass graft surgery. In the medi cation group, one patient underwent bypass surgery after 22 months of treatment. The HMTT studies of these patients at follow-up were considered as end of study measurements. One patient in the LDL apheresis group who was admitted to the hospital for unstable angina pectoris 12 months after the start of the LDL apheresis underwent percutaneous transluminal coronary angioplasty of the LAD and the RCA. After coronary angioplasty, LDL apheresis was continued, but the two perfu sion areas were excluded from assessment of regional myocar dial perfusion. In 35 patients (83% [18 in the LDL apheresis group, 17 in the medication group]), comparative data from 12 the first study and subsequent follow-up were available. Paired data were missing in seven patients because of 1) insufficient image quality from one session in two patients and from both sessions in a third patient with chronic airway obstruction; 2) loss of stored digital images from one session in two patients; and 3) no comparable DSA in two patients.
Evaluation of myocardial perfusion based on individual
ROIs. In total, 121 comparative ROIs were available, 68 in the LDL apheresis group and 53 in the medication group (mean 3.5 ± 1.7/patient). One hundred three ROIs were generated in regions supplied by native coronary arteries and 18 supplied by bypass grafts. On the basis of the ROIs, the average HMTT JACC Vol. 28, No. 7 December 1996 :1696 AENGEVAEREN ET AL.
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LDL APHERESrS IMPROVES REGIONAL MYOCARDIAL PERFUSION decreased by 0.59 ± 1.01 s in the LDL apheresis group (p < 0.0001) and by 0.10 ± 1.16 s (p = 0.52) in the medication group (0.48-s between-group difference, p = 0.01). Evaluation of regional myocardial perfusion (Table 2) , Base line HMTT values for the LDL apheresis and medication groups were 3.35 ± 1.18 s (n = 42) and 2.95 ± 1.06 s (n = 35), respectively, and were statistically not different (p = 0.52), The relative changes in HMTT in the three perfusion areas of the LA D , LCx and RCA are shown in Figure 3 . All three coronaiy perfusion areas in the LDL apheresis group contributed equally to the final result.
Patient-based analysis. In the patient-based analysis the average HMTT value in the LDL apheresis group (n = 18) was 3.19 ± 0.78 s at baseline and 2,74 ± 0.68 s at follow-up (mean difference -0.45 s [-14%], p = 0.01). In the medication group (n = 17), the average HMTT value was 2.99 ± 0.84 s at baseline and 2.94 ± 0.77 s at follow-up (mean difference -0.05 s [-2%], p = 0.85), for a mean difference in change between the two groups of 0.40 s (p -0.19).
Hematocrit measured at cardiac catheterization in the LDL apheresis group was 0.44 ± 0.03 at baseline and 0.43 ± 0.04 liter/liter at follow-up (p = 0.23) and 0.45 ± 0.03 and (P 0.44). For correction of possible changes in blood viscosity due to changes in hematocrit, the mean patient-based HMTT at follow-up catheterization was corrected by the percent change in hematocrit from baseline to follow-up catheterization. In the LDL apheresis group (n = 18), the average HMTT corrected for hematocrit change decreased from 3.19 ± 0.78 s at baseline to 2,78 ± 0.69 s at follow-up (p = 0.008) and from 2.99 ± 0.84 s at baseline to 2.97 ± 0.84 s at follow-up in the medication group (p = 0.94). The mean difference in HMTT between the LDL apheresis group and the medication group after correction for hematocrit was 0.38 s (p = 0.22), rather than 0.40 s without correction for hematocrit changes.
There were no significant correlations between the change in percent as well as absolute changes in HMTT with the mean lipid levels during the trial [total cholesterol, LDL cholesterol, high density lipoprotein cholesterol, ratio of LDL to high density lipoprotein cholesterol, lipoprotein(a)] or relative and absolute changes in lipid levels. No significant correlations were found between percent changes as well as absolute changes in HMTT and minimal obstruction diameter, mean segment diameter and time to 1-mm ST segment depression. Classification of the patients into two groups (improvement vs. no change in or impairment of time to 1-mm ST segment depression at exercise test) showed a decrease in HMTT of 16 ± 21% in the group with improvement versus an increase in HMTT of 4 ± 19% in the group with no change or impairment (p = 0.04). The change in hematocrit at cardiac catheterization was not related to the time to 1-mm ST segment depression or to the change in HMTT.
Discussion
Although the LAARS trial showed no significant change in quantitatively assessed coronary anatomy in both groups, the results of the HMTT measurements showed an increase in myocardial perfusion in the LDL apheresis group, whereas the medication-only group remained in stable condition. This improvement in myocardial perfusion in the LDL apheresis group is in agreement with the improved ischemic threshold that has been previously reported (11, 36) . These results show a discrepancy between anatomic and physiologic variables in the assessment of coronary atherosclerosis. The improved functional status in the LDL apheresis group was accompanied by a lower LDL cholesterol level (1.1 mmol/liter) than in the medication-only group. To explain the improvement in myo cardial perfusion, we hypothesized that one or more of the following mechanisms may be operative:
1.
Recovery of endothelial nitric oxide production and release in the conduit vessels. Recent studies in animals and humans (21) (22) (23) (24) (25) 37) associate hypercholesterolemia and increased Lp(a) levels with impaired endothelium-dependent vasodila tion. Lipid lowering during 6 months to 1 year may enhance endothelial function, as assessed with acetylcholine (27) (28) (29) . improvement in endothelial function may enhance exercise-1702 AENGEVAEREN ET AL. LDL APHERESIS IMPROVES REGIONAL MYOCARDIAL PERFUSION JACC VoL 28, No. 7 December 1996 :1696 induced dilation of the large epicardial coronary arteries (21, 38) . Short-term cholesterol lowering with LDL apheresis directly improves endothelium-dependent relaxation of the epicardial coronary arteries, suggesting a direct effect of LDL cholesterol (39) . The more pronounced lipid lowering in the LDL apheresis group in this study may result in better recovery of endothelial function and may thus improve the ischemic threshold at exercise testing. Assessment of HMTT reveals a time variable that is inversely related to maximal myocardial perfusion. Because of the method of assessment of HMTT (intracoronary papaverine and sublingual isosorbide dinitrate), it is unlikely that endothelium-dependent vasodilation is in volved in the improved regional myocardial perfusion observed in this study.
2, Remodeling of the conduit vessel w all Progression or regression of coronaiy arteiy stenosis may be associated with complex shape changes or remodeling (40) , in which the integrated hemodynamic effects on the coronary circulation may differ from the changes in minimal obstruction diameter and mean segment diameter. According to Glagov et al. (41) and Stiel et al. (42) , progression of coronary artery disease leads initially to compensatory dilation. In the setting of regression of atherosclerotic plaques, this process might be reversed, with remodeling of the vessel wall without a signifi cant effect on lumen cross-sectional area of the epicardial coronary arteries. However, the dilation of the remodeled coronary arteries in response to papaverine may be enhanced, and maximal myocardial perfusion may be increased. This view is supported by a recent publication (43) in which the epicar dial response to intracoronary nitroglycerin administration decreased significantly with increasing atherosclerotic wall thickening. Next to obstruction of the vascular lumen, athero sclerosis of the arterial wall also has an endotheliumindependent effect on coronary vasomotion and flow. Decrease in atherosclerotic thickening of the arterial wall without a direct effect on the lumen size of the vessel may explain the observation that functional improvement precedes anatomic regression of atherosclerosis.
3. Improved arteriolar vasodilation. Resistance vessels are spared from the development of overt atherosclerosis. How ever, relaxation of these vessels may be reduced in patients with high LDL cholesterol levels due to alterations in endo thelial cell function, as established in primates (23) . Endothelium-dependent arteriolar relaxation was impaired, whereas endothelium-independent responses were nearly identical (23) . In the human forearm model, the impairment of microvascular vasodilator function in patients with hypercho lesterolemia is endothelium-dependent only (25) ; thus, im provement in endothelium-independent arteriolar vasodilation as a mechanism for our results is highly speculative. Another hypothesis, introduced by Gould et al. (44) , is that the coronary flow response induced by direct effect of an arteriolar vasodi lator may be augmented by further improvement in flowmediated, endothelium-dependent epicardial coronary artery vasodilation. However, this effect was not likely to occur in this study, where patients received isosorbide dinitrate for epicar-diai coronary artery vasodilation before angiography. Maximal epicardial vasodilation after sublingual isosorbide dinitrate is known (45, 46) to persist for 30 to 60 min, which was the time needed in this study to perform angiography and DSA. 4 . Changes in blood rheology. Improved myocardial perfu sion might be due to changes in blood rheology as a result of repeated LDL apheresis (47, 48) . Because of this observation, assessment of HMTT in the present study was performed 1 month after final LDL apheresis to avoid a direct effect of LDL apheresis on viscosity. In LDL apheresis over dextran sulfate cellulose columns, plasma fibrinogen, a determinant of viscos ity, is lowered acutely by 26% to 35%, returning to pretreat ment levels between 2 and 7 days (11, 49) . Seven days after LDL apheresis plasma viscosity is unchanged, but blood vis cosity is still reduced, independent of the change in hematocrit (48) . Rigidity of red blood cells is increased in patients with high LDL cholesterol values, causing elevated blood viscosity. Low density lipoprotein apheresis improves the erythrocyte deformability, but how long this effect lasts after multiple procedures is unknown. In the study of Rubba et al. (48) , 3 weeks after the last of six procedures for LDL apheresis, peak blood flow in the leg was significantly increased, whereas that in the forearm was unchanged. During our study, there was a small decrease in hematocrit in the LDL apheresis group, but at cardiac catheterization the hematocrit levels were not significantly different within and between both groups. The results of HMTT analysis after correction for change in hematocrit were virtually unchanged; we therefore decided to use the original data set for the entire analysis.
In our opinion, two of the four potential mechanisms are the most attractive explanations for the improved myocardial perfusion in the LDL apheresis group. 1) The concept of the remodeling of the vessel wall. It is conceivable that although lumen dimensions have not (yet) changed significantly, the total atherosclerotic burden of the vessel wall has decreased ("reversed Glagov sequence"), conditioning the vessel wall for an increased response to a muscle relaxant such as papaverine. In our study, lumen dimensions were assessed after adminis tration of isosorbide dinitrate but without papaverine, whereas HMTT measurements were performed both after isosorbide dinitrate and papaverine. 2) The improved rheologic condition caused by LDL apheresis. The circumstantial evidence that viscosity remained unchanged between baseline and follow-up catheterization because of unchanged hematocrit and un changed fibrinogen might be insufficient. Whole-blood viscos ity is determined by many other factors, such as erythrocyte deformability and triglyceride and total cholesterol levels. Decreased whole-blood viscosity might have contributed to the improved maximal myocardial perfusion.
Further lipid-lowering studies should use intracoronary echocardiography to evaluate the total atherosclerotic burden and the existence of a "reversed Glagov sequence," combined with analysis of the vascular reaction to papaverine. Further more, analysis of whole-blood viscosity is needed to under stand the basic interactions between lipid-lowering, viscosity, LDL APHERESIS IMPROVES REGIONAL MYOCARDIAL PERFUSION endothelium-dependent and endothelium-independent vascu lar responses and myocardial perfusion.
Limitations of the study. The HMTT is inversely related to flow if the vascular volume remains constant: t = V/F, where t = mean transit time; F = flow; and V -vascular volume between the site of injection and point of measurement. Assessment of HMTT was based on the assumption that vascular volume after intracoronary papaverine administration was maximal and equal at baseline and follow-up cardiac catheterization. Theoretically, if vascular volume were smaller because of atherosclerosis and flow remained the same, a shorter mean transit time could also be found that erroneously could be interpreted as favorable. This type of error is very unlikely because vascular volume is mainly determined by arterioles and capillaries, vessels that are not involved in the atherosclerotic process. In addition, the unchanged mean segment diameter in this study supports the assumption that the vascular volume of the conduit vessels remained un changed.
In this study, regional myocardial perfusion was assessed as the primary end point for flow evaluation. For patient-based H M TT values, regions from one patient were averaged to one H M TT value. However, in some patients only one region was available; in one patient even based on only one ROI. In the other patients, eight ROIs in three myocardial perfusion areas w ere available (including bypass evaluation). Therefore, patient-based HMTT values are not always representative of the entire myocardial perfusion in that patient.
Conclusions. Biweekly LDL apheresis plus simvastatin im proved regional myocardial perfusion in patients with severe hypercholesterolemia and extensive coronaiy artery disease, In the control group, treated with lipid-lowering drugs only, regional myocardial perfusion remained stable. The improve m ent in myocardial perfusion is in agreement with that in ischemic threshold at exercise testing. The additional decrease in LDL cholesterol levels from LDL apheresis may be one explanation for the functional improvement in coronary circu lation, although rheologic changes cannot be ruled out. Func tional improvement may be due to endothelium-dependent or endothelium-independent changes, or both, in the coronaiy circulation. Further studies will be needed for elucidation of the exact mechanism. Calculation of the regional myocardial perfusion by DSA with videodensitometric calculation of the HMTT is feasible for evaluation of lipid-lowering trials, This method requires some minor modifications of the radiographic equipment and intensive instructions for the patient for breath holding. Assessment of regional myocardial perfusion in lipidlowering studies has the benefit of combined evaluation of the epicardial coronary tree as well as the microcirculation.
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